Immunotherapy of Targeting MDSCs in Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 22

PMID 36131911

Authors

Hongshu Sui

Shengyi Dongye

Xiaocui Liu

Xinghua Xu

Li Wang

Christopher Q Jin

Minhua Yao

Zhaoqing Gong

Daniel Jiang

Kexin Zhang

Yaling Liu

Hui Liu

Guomin Jiang

Yanping Su

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

HDAC1-3 inhibition triggers NEDD4-mediated CCR2 downregulation and attenuates immunosuppression in myeloid-derived suppressor cells.

Xie Z, Shao J, Shen Z, Ye Z, Okada Y, Okuzaki D Cancer Immunol Immunother. 2025; 74(3):81.

PMID: 39891718 PMC: 11787094. DOI: 10.1007/s00262-024-03931-y.

γδ T Are Significantly Impacted by CLL Burden but Only Mildly Influenced by M-MDSCs.

Zarobkiewicz M, Kowalska W, Szymanska A, Lehman N, Kowalczyk B, Tomczak W Cancers (Basel). 2025; 17(2).

PMID: 39858035 PMC: 11763719. DOI: 10.3390/cancers17020254.

PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma.

Zhang X, Sun K, Zhong B, Yan L, Cheng P, Wang Q Clin Transl Oncol. 2025; .

PMID: 39825997 DOI: 10.1007/s12094-024-03840-7.

References

Veglia F, Sanseviero E, Gabrilovich D . Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021; 21(8):485-498. PMC: 7849958. DOI: 10.1038/s41577-020-00490-y. View

Greene S, Robbins Y, Mydlarz W, Huynh A, Schmitt N, Friedman J . Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2019; 26(6):1420-1431. PMC: 7073293. DOI: 10.1158/1078-0432.CCR-19-2625. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Zaimy M, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A . New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017; 24(6):233-243. DOI: 10.1038/cgt.2017.16. View

Theivanthiran B, Evans K, DeVito N, Plebanek M, Sturdivant M, Wachsmuth L . A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020; 130(5):2570-2586. PMC: 7190922. DOI: 10.1172/JCI133055. View

Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y . Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020; 111(9):3132-3141. PMC: 7469863. DOI: 10.1111/cas.14541. View

Yang Z, Guo J, Weng L, Tang W, Jin S, Ma W . Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol. 2020; 13(1):10. PMC: 6995114. DOI: 10.1186/s13045-020-0843-1. View

Hausman D . What Is Cancer?. Perspect Biol Med. 2019; 62(4):778-784. DOI: 10.1353/pbm.2019.0046. View

Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P . Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2022; 12:799455. PMC: 8777268. DOI: 10.3389/fimmu.2021.799455. View

10.

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

11.

Jackaman C, Tomay F, Duong L, Abdol Razak N, Pixley F, Metharom P . Aging and cancer: The role of macrophages and neutrophils. Ageing Res Rev. 2017; 36:105-116. DOI: 10.1016/j.arr.2017.03.008. View

12.

Ostrand-Rosenberg S, Sinha P, Beury D, Clements V . Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012; 22(4):275-81. PMC: 3701942. DOI: 10.1016/j.semcancer.2012.01.011. View

13.

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

14.

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View

15.

Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim R, Ong S . Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. Cancer Res. 2021; 81(12):3295-3308. PMC: 8776246. DOI: 10.1158/0008-5472.CAN-20-3564. View

16.

Wright G, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec M, Bigler M . Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003; 171(6):3034-46. DOI: 10.4049/jimmunol.171.6.3034. View

17.

Zhang Md J, Zhang Md L, Yang Md Y, Liu Md Q, Ma Md H, Huang Md A . Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8 T Cells. Int J Radiat Oncol Biol Phys. 2020; 109(5):1533-1546. DOI: 10.1016/j.ijrobp.2020.11.038. View

18.

Najjar Y, Rayman P, Jia X, Pavicic Jr P, Rini B, Tannenbaum C . Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2016; 23(9):2346-2355. PMC: 5411325. DOI: 10.1158/1078-0432.CCR-15-1823. View

19.

Lemke G, Rothlin C . Immunobiology of the TAM receptors. Nat Rev Immunol. 2008; 8(5):327-36. PMC: 2856445. DOI: 10.1038/nri2303. View

20.

Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C . Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020; 130(10):5380-5396. PMC: 7524481. DOI: 10.1172/JCI137110. View